How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients with CAIX-positive Cancer
Description:
Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.
Sponsor:
Philogen S.p.A.
Contacts:
Jacqueline Mock, PhDregulatory@philogen.com
+41 43 544 88 02
Federica Bastioli (Pharmaceutical Chemist)regulatory@philogen.com
+39 057717816
Government Study Link:
NCT06840548 - Click here to see study onClinicalTrials.gov
68Ga-OncoCAIX
Isotope(s):
Target(s):
- CAIX
